Origene Technologies
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Grant | ||
$16.0m | Series B | ||
N/A | $15.0m | Late VC | |
$21.3m | Series C | ||
$17.1m | Late VC | ||
Total Funding | $69.4m |
Related Content
Recent News about Origene Technologies
EditOriGene Technologies, Inc. operates in the biotechnology sector, providing a wide range of gene-based research tools and reagents. The company serves academic, pharmaceutical, and biotech researchers by offering products such as cDNA clones, antibodies, proteins, RNAi, and lentiviral particles. OriGene's business model is centered on the production and distribution of high-quality research reagents, leveraging a large inventory and a distributed manufacturing chain to ensure timely delivery. Revenue is generated through the direct sale of these products to research institutions and companies worldwide. The company is known for its extensive catalog, which includes over 37,000 human full-length ORF cDNA clones, 50,000 primary antibodies, and 10,000 human proteins, among other research tools. OriGene also provides educational resources such as videos, webinars, and scientific posters to support the research community.
Keywords: cDNA clones, antibodies, proteins, RNAi, lentiviral particles, gene-based research, biotechnology, research reagents, academic researchers, pharmaceutical.